ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa

Completed

Conditions: Hidradenitis Suppurativa (HS)

First Posted Date: 2019-03-29

Last Posted Date: 2022-11-03

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT03894956

Locations: 🇯🇵
Anjou Kousei Hospital /ID# 216741, Anjo-shi, Aichi, Japan
🇯🇵
Kimitsu Chuo Hospital /ID# 214733, Kisarazu-shi, Chiba, Japan
🇯🇵
NHO Nagoya Medical Center /ID# 214406, Nagoya-shi, Aichi, Japan

and more 34 locations

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors
Cancer
Triple-Negative Breast Cancer (TNBC)
Non-small-cell-lung-cancer (NSCLC)
Metastatic Solid Tumors

Interventions: Drug: ABBV-927
Drug: ABBV-368
Drug: ABBV-181
Drug: Carboplatin
Drug: Nab-paclitaxel

First Posted Date: 2019-03-28

Last Posted Date: 2024-08-14

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT03893955

Locations: 🇪🇸
Hospital Universitario Fundacion Jimenez Diaz /ID# 212806, Madrid, Spain
🇦🇺
Icon Cancer Centre /ID# 224084, South Brisbane, Queensland, Australia
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072, Fort Wayne, Indiana, United States

and more 23 locations

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Phase 3

Conditions: Ocular Hypertension
Open-Angle Glaucoma

Interventions: Drug: Bimatoprost SR
Other: Standard of Care

First Posted Date: 2019-03-27

Last Posted Date: 2024-02-13

Lead Sponsor: AbbVie

Target Recruit Count: 600

Registration Number: NCT03891446

Locations: 🇺🇸
Lakeside Vision Center /ID# 240204, Irvine, California, United States
🇺🇸
The Eye Research Foundation /ID# 240186, Newport Beach, California, United States
🇺🇸
Wolstan & Goldberg Eye Associates /ID# 240221, Torrance, California, United States

and more 121 locations

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Phase 4

Completed

Conditions: Uterine Fibroids

Interventions: Drug: Placebo
Drug: Elagolix

First Posted Date: 2019-03-22

Last Posted Date: 2022-03-31

Lead Sponsor: AbbVie

Target Recruit Count: 82

Registration Number: NCT03886220

Locations: 🇺🇸
Johns Hopkins University /ID# 211135, Baltimore, Maryland, United States
🇺🇸
Caceres Specialized Gynecology /ID# 214956, Kissimmee, Florida, United States
🇺🇸
Georgia Research for Women /ID# 211321, Atlanta, Georgia, United States

and more 45 locations

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Placebo solution for risankizumab
Drug: Risankizumab

First Posted Date: 2019-03-14

Last Posted Date: 2021-03-16

Lead Sponsor: AbbVie

Target Recruit Count: 157

Registration Number: NCT03875482

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 212559, Anaheim, California, United States
🇺🇸
Skin Laser and Surgery Specialists of NY and NJ /ID# 210208, Hackensack, New Jersey, United States
🇺🇸
Arlington Research Center, Inc /ID# 210344, Arlington, Texas, United States

and more 40 locations

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Cancer

Interventions: Drug: Venetoclax

First Posted Date: 2019-03-14

Last Posted Date: 2023-09-01

Lead Sponsor: AbbVie

Target Recruit Count: 71

Registration Number: NCT03873857

Locations: 🇷🇺
Clinical Medico-Sanitary Unit #1 /ID# 212364, Perm, Russian Federation
🇷🇺
Republican Hospital #1 - National Center of Medicine of Sakha (Yakutia) /ID# 212371, Yakutsk, Russian Federation
🇷🇺
Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 212372, Sankt-Peterburg, Russian Federation

and more 17 locations

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Risankizumab
Device: Autoinjector

First Posted Date: 2019-03-14

Last Posted Date: 2021-05-11

Lead Sponsor: AbbVie

Target Recruit Count: 108

Registration Number: NCT03875508

Locations: 🇺🇸
Tien Q Nguyen MD, Inc /ID# 210775, Fountain Valley, California, United States
🇺🇸
Advanced Research Associates /ID# 210634, Glendale, Arizona, United States
🇺🇸
Bakersfield Derma & Skin Cance /ID# 210773, Bakersfield, California, United States

and more 23 locations

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
T-cell Prolymphocytic Leukemia (T-PLL)
Cancer

Interventions: Drug: Venetoclax
Drug: Ibrutinib

First Posted Date: 2019-03-13

Last Posted Date: 2022-12-19

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT03873493

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center /ID# 207746, Houston, Texas, United States
🇬🇧
Oxford University Hospitals NHS Foundation Trust /ID# 211264, Oxford, Oxfordshire, United Kingdom
🇳🇱
Maxima Medisch Centrum /ID# 207989, Eindhoven, Netherlands

and more 12 locations

Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation

Completed

Conditions: Chronic Hepatitis C (CHC)

First Posted Date: 2019-03-08

Last Posted Date: 2021-08-30

Lead Sponsor: AbbVie

Target Recruit Count: 161

Registration Number: NCT03868163

Locations: 🇷🇺
LLC Medical Company Hepatolog /ID# 212384, Samara, Samarskaya Oblast, Russian Federation
🇷🇺
A. F. Agafonov Republican Clin /ID# 212381, Kazan, Tatarstan, Respublika, Russian Federation
🇷🇺
Clinical Inf. Dis Hospital 1 /ID# 217033, Novosibirsk, Russian Federation

and more 6 locations

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Phase 4

Terminated

Conditions: Exocrine Pancreatic Insufficiency (EPI)

Interventions: Drug: Pancrelipase
Drug: Placebo

First Posted Date: 2019-03-01

Last Posted Date: 2023-06-05

Lead Sponsor: AbbVie

Target Recruit Count: 1

Registration Number: NCT03859869

Locations: 🇺🇸
Fox Chase Cancer Center /ID# 202288, Philadelphia, Pennsylvania, United States
🇺🇸
NorthShore University HealthSystem /ID# 209026, Evanston, Illinois, United States
🇺🇸
East Carolina University /ID# 206661, Greenville, North Carolina, United States

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy